Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.

Now the shortages of Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound are over. The FDA determined in December and February, respectively, that the companies could meet demand.

From Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to cover? Let us know! Ever since blockbuster weight-loss drugs like Wegovy and Zepbound went mainstream, ...

Hims teamed up with Novo Nordisk A/S in April to offer its rival drug Wegovy at a discounted price to patients who use its platform. The telehealth company — and its investors — had been ...